Rep. Robert Bresnahan, Jr. Sells UnitedHealth Group Incorporated (NYSE:UNH) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of UnitedHealth Group Incorporated NYSE: UNH. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $15,001 and $50,000 in UnitedHealth Group stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.

UnitedHealth Group Price Performance

NYSE:UNH traded down $0.85 on Wednesday, reaching $300.37. The stock had a trading volume of 11,193,888 shares, compared to its average volume of 6,894,771. The company has a market capitalization of $272.48 billion, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 1.37 and a beta of 0.56. The stock has a fifty day moving average price of $422.31 and a 200-day moving average price of $489.42. The company has a quick ratio of 0.91, a current ratio of 0.83 and a debt-to-equity ratio of 0.74. UnitedHealth Group Incorporated has a 1-year low of $248.88 and a 1-year high of $630.73.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its quarterly earnings data on Thursday, April 17th. The healthcare conglomerate reported $7.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.29 by ($0.09). UnitedHealth Group had a net margin of 3.60% and a return on equity of 26.69%. The business had revenue of $109.58 billion during the quarter, compared to the consensus estimate of $111.56 billion. During the same quarter in the previous year, the firm posted $6.91 EPS. Research analysts forecast that UnitedHealth Group Incorporated will post 29.54 EPS for the current year.

Hedge Funds Weigh In On UnitedHealth Group

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in UnitedHealth Group by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 90,729,585 shares of the healthcare conglomerate's stock valued at $47,519,620,000 after acquiring an additional 5,583,343 shares in the last quarter. Wellington Management Group LLP raised its position in UnitedHealth Group by 10.6% in the 1st quarter. Wellington Management Group LLP now owns 25,847,940 shares of the healthcare conglomerate's stock valued at $13,537,859,000 after buying an additional 2,486,839 shares during the last quarter. Geode Capital Management LLC boosted its position in UnitedHealth Group by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 19,956,219 shares of the healthcare conglomerate's stock worth $10,068,869,000 after acquiring an additional 319,515 shares during the last quarter. Capital International Investors raised its holdings in shares of UnitedHealth Group by 6.2% in the fourth quarter. Capital International Investors now owns 15,616,007 shares of the healthcare conglomerate's stock valued at $7,899,905,000 after purchasing an additional 906,365 shares during the last quarter. Finally, Norges Bank acquired a new position in UnitedHealth Group during the fourth quarter worth $6,375,744,000. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on UNH. Morgan Stanley dropped their target price on shares of UnitedHealth Group from $563.00 to $374.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Robert W. Baird reduced their price objective on UnitedHealth Group from $510.00 to $356.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. TD Securities reissued a "hold" rating and issued a $308.00 target price (down from $520.00) on shares of UnitedHealth Group in a research note on Monday, May 19th. Raymond James cut UnitedHealth Group from a "strong-buy" rating to a "market perform" rating in a report on Wednesday, May 14th. Finally, Piper Sandler cut their target price on shares of UnitedHealth Group from $552.00 to $353.00 and set an "overweight" rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, UnitedHealth Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $428.43.

Insider Buying and Selling at UnitedHealth Group

In related news, CFO John F. Rex acquired 17,175 shares of the company's stock in a transaction dated Friday, May 16th. The shares were bought at an average price of $291.12 per share, for a total transaction of $4,999,986.00. Following the purchase, the chief financial officer now directly owns 203,796 shares in the company, valued at approximately $59,329,091.52. This trade represents a 9.20% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy Patrick Flynn purchased 1,533 shares of the company's stock in a transaction on Wednesday, May 14th. The shares were purchased at an average cost of $320.80 per share, for a total transaction of $491,786.40. Following the completion of the transaction, the director now directly owns 6,033 shares of the company's stock, valued at approximately $1,935,386.40. This represents a 34.07% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 109,408 shares of company stock worth $31,607,768. Insiders own 0.33% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.